Refining Early Antitumoral Drug Development

Refining Early Antitumoral Drug Development

The failure rate of development of new drugs in oncology is high, with up to 95% of drugs tested in Phase I not reaching the market. Causes behind this high failure rate are discussed here, and solutions to increase the success in the development of antitumor drugs are suggested.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Trends in pharmacological sciences (Regular ed.) 2018-11, Vol.39 (11), p.922-925
Hauptverfasser: Ocaña, Alberto, García-Alonso, Sara, Amir, Eitan, Pandiella, Atanasio
Format: Artikel
Sprache:eng
Schlagworte:
drug development
oncology
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The failure rate of development of new drugs in oncology is high, with up to 95% of drugs tested in Phase I not reaching the market. Causes behind this high failure rate are discussed here, and solutions to increase the success in the development of antitumor drugs are suggested.
ISSN:0165-6147
1873-3735
DOI:10.1016/j.tips.2018.09.003